Private Market View

Marrow Access Technologies

Eden Prairie, MN · Founded 2017 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
$990K
Last round

Key facts

  • It has raised $990K; the latest was Later Stage VC ($100K) in Apr 2026.
  • Notable investors include Plug and Play Tech Center, KOFA Healthcare, Minnesota Department of Employment and Economic Development.
  • Marrow Access Technologies has filed 1 Form D with the SEC, most recently Jun 2024 ($241K sold to 2 investors).
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 3 names
  • ·Watchlist + deal alerts for Marrow Access Technologies
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Marrow Access Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Marrow Access Technologies

Developer of orthopedic surgical devices designed for marrow stimulation therapy. The company's devices utilize a patented mechanism to create clean, deep, precise channels into the bone to stimulate the patient's healing reaction to repair and regenerate cartilage and other soft tissue, enabling healthcare professionals to help with cartilage defects to heal the bones in a less invasive way.

Sector
Healthcare
HQ
Eden Prairie, MN, United States
Founded
2017
Employees
7
Ownership
Privately Held (backing)
PA Mark — not yet priced

Marrow Access Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Marrow Access Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Marrow Access Technologies in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.